When was MitoRx Therapeutics founded?

MitoRx Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is MitoRx Therapeutics located?

MitoRx Therapeutics is headquartered in Harwell, United Kingdom.

Who is the current CEO of MitoRx Therapeutics?

Jon Rees of MitoRx Therapeutics. They have also founded 1 company.

Which legal entities is MitoRx Therapeutics associated with?

MitoRx Therapeutics is associated with MITORX THERAPEUTICS LIMITED.

How many employees does MitoRx Therapeutics have?

As of May 31, 2026, the latest employee count at MitoRx Therapeutics is 13.

Is MitoRx Therapeutics a funded company?

MitoRx Therapeutics is a funded company, having raised a total of $12.2M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 25, 2022.

When was the latest funding round of MitoRx Therapeutics?

MitoRx Therapeutics' latest funding was a $***** Seed round on Nov 17, 2025, with participation from 1 investor.

Where does MitoRx Therapeutics rank among its competitors?

MitoRx Therapeutics ranks 19th amongst 154 active competitors, of which 54 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Adocia, which secured $11.7M in Dec, 2025.

Who are the top competitors of MitoRx Therapeutics?

MitoRx Therapeutics' top competitors include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Among them, Adocia secured the most recent funding round in December, 2025.

MitoRx Therapeutics - 2026 Company Profile, Team, Funding & Competitors

MitoRx Therapeutics is a seed company based in Harwell (United Kingdom), founded in 2021 by Matt Whiteman, Norman Law and Jon Rees. It operates as a Developer of new treatments to restore healthy mitochondrial metabolism in patients. MitoRx Therapeutics has raised $12.2M in funding from investors like Oxford Technology, Wren Capital and UK Innovation Science & Seed Fund. The company has 154 active competitors, including 54 funded and 45 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Adocia.

Company Details

Developer of new treatments to restore healthy mitochondrial metabolism in patients. The company's small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs, in people with metabolically unhealthy obesity, by resetting mitochondrial function rather than suppressing appetite.

Website: mitorxtherapeutics.com
Social
Email ID: *****@mitorxtherapeutics.com
Phone Number: +44 **********

Key Metrics

Founded Year

2021

Location

Harwell, United Kingdom

Stage

Seed

Total Funding

$12.2M in 3 rounds

Latest Funding Round

Seed, Nov 17, 2025, $*****

Investors

Oxford Technology & 22 more

Ranked

19^th among 154 active competitors

Employee Count

13 as on May 31, 2026

Similar Companies

Adocia & 123 more

View MitoRx Therapeutics' full profile

MitoRx Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MITORX THERAPEUTICS LIMITED CIN: 13237941 , Germany, Active	Mar 01, 2021	-	4 (As on Mar 31, 2023)

MitoRx Therapeutics has raised a total funding of $12.2M over 3 rounds. Its first funding round was on Apr 25, 2022. Its latest funding round was a Seed round on Nov 17, 2025 for $*****. 1 investor participated in its latest round. MitoRx Therapeutics has 10 institutional investors and 13 angel investors.

Here is the list of recent funding rounds of MitoRx Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2025	6174829	Seed	2115795	9961372	8319275	1321101
Dec 13, 2023	2322001	Seed	6617454	3973895	9935552	9595318
Apr 25, 2022	1835798	Seed	9732789	8922111	3416923	Wren Capital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of MitoRx Therapeutics's funding rounds and investors

The founders of MitoRx Therapeutics are Matt Whiteman, Norman Law and Jon Rees. Jon Rees is the CEO of MitoRx Therapeutics.

Here are the details of MitoRx Therapeutics' key team members:

Matt Whiteman: Co-Founder & CSO of MitoRx Therapeutics.
Norman Law: Co-Founder & CTO of MitoRx Therapeutics.
Jon Rees: Co-Founder & CEO of MitoRx Therapeutics.

MitoRx Therapeutics' Board of Directors

MitoRx Therapeutics's board has 6 active members. Glyn Owain Edwards, Jonathan David Rees, Dr Norman Milne Law and Matthew Loren Whiteman are part of team and The Honourable Alexander Michael Fink and Dr David Mark Anthony Holbrook are independent board members.

Here is the list of MitoRx Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Jonathan David Rees	Team	-	Current	5y 3m
Dr Norman Milne Law	Team	-	Current	5y 3m
Matthew Loren Whiteman	Team	-	Current	4y 9m
dcbj{dj	Team	-	Current	7y 2m
The Honourable Alexander Michael Fink	Independent board member	-	Current	4y 1m
ifosnkk	Independent board member	-	Current	7y 9m

View details of MitoRx Therapeutics's Founder profiles and Board Members

MitoRx Therapeutics' employee count trend

MitoRx Therapeutics has 13 employees as of May 26. Here is MitoRx Therapeutics's employee count trend over the years:

Employee count trend for MitoRx Therapeutics

Uncover MitoRx Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MitoRx Therapeutics include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of MitoRx Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, BioBrit & 7 others	68/100
5th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Perceptive Advisors & 5 others	65/100
6th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Orbimed, Longitude Capital & 3 others	64/100
7th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
8th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Cathay Financial Holdings, Shire & 18 others	63/100
9th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 29 others	63/100
10th	BioAge Labs Emeryville (United States), Public	Provider of a bioinformatics platform for biomarkers and drug discovery	$294M	Andreessen Horowitz, Felicis Ventures & 26 others	62/100
19th	MitoRx Therapeutics 2021, Harwell (United Kingdom), Seed	Developer of new treatments to restore healthy mitochondrial metabolism in patients	$12.2M	Longevitytech.fund, Oxford Technology & 21 others	59/100